136 related articles for article (PubMed ID: 32233172)
1. Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea.
Kim HK; Choi SM; Kang G; Park KH; Lee DG; Park WB; Rhee SJ; Lee S; Jung SI; Jang HC
Yonsei Med J; 2020 Apr; 61(4):301-309. PubMed ID: 32233172
[TBL] [Abstract][Full Text] [Related]
2. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.
Vesga O; Agudelo M; Salazar BE; Rodriguez CA; Zuluaga AF
Antimicrob Agents Chemother; 2010 Aug; 54(8):3271-9. PubMed ID: 20547818
[TBL] [Abstract][Full Text] [Related]
3. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Antimicrob Agents Chemother; 2012 Jan; 56(1):243-7. PubMed ID: 22064531
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
Agudelo M; Vesga O
Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States.
Louie A; Boyne MT; Patel V; Huntley C; Liu W; Fikes S; Kurhanewicz S; Rodriquez J; Robbins N; Brown D; Baluya D; Drusano GL
Antimicrob Agents Chemother; 2015 Jan; 59(1):622-32. PubMed ID: 25385113
[TBL] [Abstract][Full Text] [Related]
6. Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.
Tattevin P; Saleh-Mghir A; Davido B; Ghout I; Massias L; Garcia de la Maria C; Miró JM; Perronne C; Laurent F; Crémieux AC
Antimicrob Agents Chemother; 2013 Mar; 57(3):1157-62. PubMed ID: 23254435
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
BMC Infect Dis; 2010 Jun; 10():153. PubMed ID: 20525378
[TBL] [Abstract][Full Text] [Related]
8. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
[TBL] [Abstract][Full Text] [Related]
10. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
[TBL] [Abstract][Full Text] [Related]
12. Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model.
Hirai J; Hagihara M; Kato H; Sakanashi D; Nishiyama N; Koizumi Y; Yamagishi Y; Suematsu H; Hanaki H; Mikamo H
J Infect Chemother; 2016 Jun; 22(6):387-94. PubMed ID: 27029221
[TBL] [Abstract][Full Text] [Related]
13. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
[TBL] [Abstract][Full Text] [Related]
14. In vivo antibacterial activity and pharmacological properties of the membrane-active glycopeptide antibiotic YV11455.
Yarlagadda V; Konai MM; Manjunath GB; Prakash RG; Mani B; Paramanandham K; Ranjan SB; Ravikumar R; Chakraborty SP; Roy S; Haldar J
Int J Antimicrob Agents; 2015 Jun; 45(6):627-34. PubMed ID: 25900818
[TBL] [Abstract][Full Text] [Related]
15. Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
Rodriguez CA; Agudelo M; Aguilar YA; Zuluaga AF; Vesga O
PLoS One; 2016; 11(5):e0155806. PubMed ID: 27191163
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
Lepak AJ; Marchillo K; Craig WA; Andes DR
Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus.
Fujimura S; Fuse K; Takane H; Nakano Y; Gomi K; Kikuchi T; Watanabe A
J Infect Chemother; 2011 Feb; 17(1):30-3. PubMed ID: 20665064
[TBL] [Abstract][Full Text] [Related]
18. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.
Zuluaga AF; Rodriguez CA; Agudelo M; Vesga O
BMC Res Notes; 2015 Oct; 8():546. PubMed ID: 26445936
[TBL] [Abstract][Full Text] [Related]
20. Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.
Agudelo M; Rodriguez CA; Pelaez CA; Vesga O
Antimicrob Agents Chemother; 2014; 58(2):1005-18. PubMed ID: 24277034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
